PsychoGenics Inc. today announced the establishment of an alliance with KineMed, Inc. to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.
KineMed has developed a novel analytical method to measure neuronal cell proliferation, differentiation and survival. This approach eliminates the need for the time consuming, labor intensive and often rate limiting step of histological analysis. In combination with PsychoGenics' extensive collection of animal models, it will enable an integrated assessment of the role of neurogenesis in psychiatric and neurodegenerative disorders. These new techniques for measuring the multiple stages of neurogenesis will complement and broaden PsychoGenics' in vivo and in vitro capabilities, and aid in the identification and analysis of CNS drug candidates for its numerous clients and partners.
"I am very much looking forward to working with PsychoGenics. The cutting-edge metrics of cellular dynamics in the living brain that we provide, should beautifully complement their extensive array of animal models and behavioral outcome measures. The resulting combination of contract research services and proprietary mass spectrometric technologies is extremely powerful," said Dr. Marc K. Hellerstein, M.D., Ph.D, KineMed co-founder and Chief of the Scientific Advisory Board and professor (DH Calloway Chair) at the University of California at Berkeley.
"We are excited to enter into this alliance with KineMed which will allow Psychogenics to provide our clients and partners the ability to assess the effects of compounds on behavior and neurogenesis and correlate them with other neurochemical and molecular signals such as changes in transmitter and growth factor levels in the same animal," commented David Lowe, Ph.D., PsychoGenics' Chief Scientific Officer.
VANCE trial marks milestone in t cell therapy for solid tumors